Steatohepatitis/Metabolic Liver Disease

Top Story

Interim analysis of metabolic modulators shows efficacy in NAFLD

January 14, 2020

NASHNET designates eighth center of excellence

January 9, 2020
NASHNET has designated the Central Virginia VA Health Care System as its eighth founding charter member and “center of excellence” in recognition of the…
In the Journals

Histological noninvasive tools define distinct profiles between NAFLD, NASH

January 8, 2020
Both the fatty liver inhibition of progression algorithm and the steatosis activity and fibrosis scoring system identified distinct clinical and biological profiles of…

Enrollment to test NASH drug candidate complete

January 7, 2020
Akero Therapeutics announced that it has completed enrollment for a phase 2a study of AKR-001, the company’s FGF21 analog candidate for the treatment of…
More Headlines »